Opinion

Video

Importance of Patient-Reported Outcomes

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.

Video content above is prompted by the following:

  • What is the potential impact of these novel treatments on disease progression, mortality, and patient-reported outcomes such as quality of life, survival time, and functional status?
  • An important consideration in drug development is understanding the impact on patient-reported outcomes and quality of life. How are the clinical trials for idiopathic pulmonary fibrosis agents incorporating these measures?

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo